Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2022

View Archived Issues

S2K146 protects against SARS-CoV-2 infection in preclinical models

Exon-skipping antisense oligonucleotides show promise for treating cystic fibrosis

TRAF6 loss linked to development of myeloid malignancies

Discovery of novel mGlu4 receptor PAMs with antipsychotic-like properties

Zealand Pharma divulges LPAM-1 antagonists

Array BioPharma discloses new HER2 inhibitors

Cadila Healthcare synthesizes ENPP2 inhibitors

CGeneTech identifies new CDK inhibitors

Chinese investigators describe AGTR2 antagonists

Repurposed drug promoting systemic arginine catabolism improves energy homeostasis in obese mice

Synergistic antitumor activity of rencofilstat + anti-PD-1 in mice with fatty livers and HCC

IL-2Rbeta agonist MDNA-11 shows promising results in preclinical cancer models

Somatic tissue engineering gives insights into ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...